Dr. Reddy’s Laboratories ($RDY) announced its new collaboration with Encore Dermatology. Under the terms of the deal, the company has out-licensed DFD-06, a high potency steroid for the potential treatment of plaque psoriasis. Encore will be responsible for commercialization in the U.S. Promiusof Dr. Reddy’s Laboratories will be eligible to receive up to $32.5 million in milestones and a fixed royalty on net sales.
CRISPR Therapeutics ($CRSP) reported its new two-year research collaboration with Massachusetts General Hospital Cancer Center to develop T cell therapies for cancer. The deal also has license option agreement attached to it. The companies did not disclose the financial terms of the deal.